EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity

[Image: see text] Inhibitors of the protein methyltransferase Enhancer of Zeste Homolog 2 (EZH2) may have significant therapeutic potential for the treatment of B cell lymphomas and other cancer indications. The ability of the scientific community to explore fully the spectrum of EZH2-associated pat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:ACS Med Chem Lett
Autors principals: Campbell, John E., Kuntz, Kevin W., Knutson, Sarah K., Warholic, Natalie M., Keilhack, Heike, Wigle, Tim J., Raimondi, Alejandra, Klaus, Christine R., Rioux, Nathalie, Yokoi, Akira, Kawano, Satoshi, Minoshima, Yukinori, Choi, Hyeong-Wook, Porter Scott, Margaret, Waters, Nigel J., Smith, Jesse J., Chesworth, Richard, Moyer, Mikel P., Copeland, Robert A.
Format: Artigo
Idioma:Inglês
Publicat: American Chemical Society 2015
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4434464/
https://ncbi.nlm.nih.gov/pubmed/26005520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.5b00037
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars